Soligenix announces distribution of series d preferred stock to holders of its common stock

Princeton, n.j. , dec. 23, 2022 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its board of directors declared a dividend of one one-thousandth of a share of newly designated series d preferred stock, par value $0.001 per share, for each outstanding share of the company's common stock held of record as of 5:00 p.m.
SNGX Ratings Summary
SNGX Quant Ranking